Results 11 to 20 of about 2,076,500 (256)

Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials [PDF]

open access: yesMalaria Journal, 2010
Background Phase III trials of the malaria vaccine, RTS, S, are now underway across multiple sites of varying transmission intensity in Africa. Heterogeneity in exposure, vaccine response and waning of efficacy may bias estimates of vaccine efficacy ...
Drakeley Chris J   +3 more
doaj   +2 more sources

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. [PDF]

open access: yes, 2011
BACKGROUND\ud \ud There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials.\ud \ud METHODS\ud \ud The present paper describes ...
Amanda Leach   +27 more
core   +1 more source

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. [PDF]

open access: yes, 2011
BACKGROUND\ud \ud An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.\ud \ud METHODS\ud \ud From March 2009 through January 2011, we enrolled 15,460 ...
Machera, Francisca   +282 more
core   +1 more source

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. [PDF]

open access: yes, 2010
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa.
Zijlstra, EE   +26 more
core   +1 more source

Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial [PDF]

open access: yes, 2008
Background Previous research indicates that a combination vaccine targeting different stages of the malaria life cycle is likely to provide the most effective malaria vaccine.
Zurbriggen, R   +75 more
core   +1 more source

The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine [PDF]

open access: yes, 2012
This paper estimates the marginal willingness-to-pay for attributes of a hypothetical HIV vaccine using discrete choice modeling. We use primary data from 326 respondents from Bangkok and Chiang Mai, Thailand, in 2008–2009, selected using purposive ...
Newman, Peter A.   +15 more
core   +1 more source

Predicting COVID-19 vaccine hesitancy in Hong Kong: Vaccine knowledge, risks from coronavirus, and risks and benefits of vaccination

open access: yesVaccine: X, 2022
Introduction: Hongkongers have had access to COVID-19 vaccines for about four months, but vaccination rate remains low (34.4% as of 4 July 2021). Given that vaccine uptake is vital, this study aimed to determine how vaccine-hesitant and vaccinated ...
Stephanie Jean Tsang
doaj   +1 more source

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

open access: yes, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
Machera, Francisca   +104 more
core   +1 more source

Anticipated HIV Vaccine Acceptability among Sexually Active African-American Adult Women

open access: yesVaccines, 2013
An HIV vaccine, once it becomes available, could reduce vulnerability to HIV among African-American women. The purpose of this study was to assess determinants of HIV vaccine acceptability among African-American women across hypothetical levels of ...
Mark Mulligan   +6 more
doaj   +1 more source

The Correlated Beta Dose Optimisation Approach: Optimal Vaccine Dosing Using Mathematical Modelling and Adaptive Trial Design [PDF]

open access: yes, 2022
Mathematical modelling methods and adaptive trial design are likely to be effective for optimising vaccine dose but are not yet commonly used. This may be due to uncertainty with regard to the correct choice of parametric model for dose-efficacy or dose ...
Benest, John   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy